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Summary
Background Slow and cumbersome laboratory diagnostics for Mycobacterium tuberculosis complex (MTBC) risk 
delayed treatment and poor patient outcomes. Whole-genome sequencing (WGS) could potentially provide a rapid 
and comprehensive diagnostic solution. In this prospective study, we compare real-time WGS with routine MTBC 
diagnostic workﬂ ows.
Methods We compared sequencing mycobacteria from all newly positive liquid cultures with routine laboratory 
diagnostic workﬂ ows across eight laboratories in Europe and North America for diagnostic accuracy, processing 
times, and cost between Sept 6, 2013, and April 14, 2014. We sequenced specimens once using local Illumina MiSeq 
platforms and processed data centrally using a semi-automated bioinformatics pipeline. We identiﬁ ed species or 
complex using gene presence or absence, predicted drug susceptibilities from resistance-conferring mutations 
identiﬁ ed from reference-mapped MTBC genomes, and calculated genetic distance to previously sequenced UK 
MTBC isolates to detect outbreaks. WGS data processing and analysis was done by staﬀ  masked to routine reference 
laboratory and clinical results. We also did a microcosting analysis to assess the ﬁ nancial viability of WGS-based 
diagnostics.
Findings Compared with routine results, WGS predicted species with 93% (95% CI 90–96; 322 of 345 specimens; 
356 mycobacteria specimens submitted) accuracy and drug susceptibility also with 93% (91–95; 628 of 672 specimens; 
168 MTBC specimens identiﬁ ed) accuracy, with one sequencing attempt. WGS linked 15 (16% [95% CI 10–26]) of 91 
UK patients to an outbreak. WGS diagnosed a case of multidrug-resistant tuberculosis before routine diagnosis was 
completed and discovered a new multidrug-resistant tuberculosis cluster. Full WGS diagnostics could be generated in 
a median of 9 days (IQR 6–10), a median of 21 days (IQR 14–32) faster than ﬁ nal reference laboratory reports were 
produced (median of 31 days [IQR 21–44]), at a cost of £481 per culture-positive specimen, whereas routine diagnosis 
costs £518, equating to a WGS-based diagnosis cost that is 7% cheaper annually than are present diagnostic workﬂ ows.
Interpretation We have shown that WGS has a scalable, rapid turnaround, and is a ﬁ nancially feasible method for full 
MTBC diagnostics. Continued improvements to mycobacterial processing, bioinformatics, and analysis will improve 
the accuracy, speed, and scope of WGS-based diagnosis.
Funding National Institute for Health Research, Department of Health, Wellcome Trust, British Colombia Centre for 
Disease Control Foundation for Population and Public Health, Department of Clinical Microbiology, Trinity College 
Dublin.
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Introduction
In 2013, WHO estimated that Mycobacterium tuberculosis 
complex (MTBC) caused 9 million new active infections 
and 1·5 million deaths worldwide.1 Non-tuberculous 
mycobacteria also cause considerable morbidity and 
mortality.2 Protracted MTBC diagnosis and phenotypic 
drug susceptibility testing (DST) due to slow growth in 
culture contribute to reported treatment initiation delays 
of 8–80 days from ﬁ rst contact with health services, 
risking poor clinical outcomes and transmission con-
trol.3–6 Although genotypic assays such as the Cepheid 
Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) and 
Hain line-probe (Hain Lifescience, Nehren, Germany) 
assays can rapidly (less than a day) identify mycobacterial 
species and mutations conferring MTBC drug resistance 
independent of culture, they do not detect all resistance-
conferring mutations and are typically still used after 
microbial culture.5–9 Besides identifying species and 
doing DST, high-income countries also genotype MTBC 
using mycobacterial interspersed repetitive unit-variable-
number tandem repeat (MIRU-VNTR) for outbreak 
detection.
Findings from retrospective studies6,8–19 show the 
potential for whole-genome sequencing (WGS) to predict 
drug susceptibility and simultaneously track outbreaks 
with high resolution. WGS could replace the entire 
MTBC diagnostic workﬂ ow from Mycobacteria Growth 
Indicator Tubes (MGITs; BACTEC MGIT; Beckton 
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Dickinson, Franklin Lakes, NJ, USA) thanks to 
demonstrable beneﬁ ts for outbreak detection, growing 
knowledge bases for drug resistance-conferring 
mutations, and reliable DNA isolation from newly pos-
itive culture.6,8–20 So far, to our knowledge, no investigators 
have assessed this process prospectively. In this 
prospective study, we compare real-time WGS with 
routine MTBC diagnostic workﬂ ows at Illumina MiSeq 
(Illumina, San Diego, CA, USA)-equipped laboratories 
across Europe and North America. We also do a 
microcosting analysis to assess the ﬁ nancial viability of 
WGS-based diagnostics.
Methods
Study design
Eight participating laboratories in the UK, Ireland, 
Germany, France, and Canada processed all newly 
positive MGIT cultures from specimens submitted for 
mycobacterial testing on the examining physician’s 
request between Sept 6, 2013, and April 14, 2014 
(appendix p 19). We used no other selection criteria 
(except for the German centre where only the second 
positive primary culture from MTBC patients was 
available for processing). If patients had duplicate 
specimens—eg, from diﬀ erent body sites or at diﬀ erent 
times—we included them.
Because this study assessed service delivery methods 
without returning results for clinical management, 
research ethics committee approval was not required in 
the UK. Other centres obtained local ethics committee 
approval.
Procedures
Routine diagnostic procedures at all centres included 
species identiﬁ cation (Hain GenoType MTBC/CM/AS), 
and for MTBC, MIRU-VNTR and culture with isoniazid, 
rifampicin, ethambutol, and pyrazinamide to establish 
drug susceptibility. Culture with streptomycin was also 
done in some centres. Subsequent culture of rifampicin-
resistant isolates with ﬂ uoroquinolones and amino-
glycosides was done to establish additional drug 
susceptibilities.
Each site prepared DNA and did WGS. We heat 
inactivated 1–2 mL MGIT culture aliquots at 95°C for 
0·5–2 h, adhering to local protocols, and always retaining 
suﬃ  cient MGIT culture for routine diagnostic procedures 
to avoid compromising patient care. We isolated DNA as 
previously described (appendix);20 an in-house protocol 
was used in the Canadian centre. We prepared sequencing 
libraries for the MiSeq platform using a modiﬁ ed 
Nextera XT (Illumina) protocol (appendix) and sequenced 
pools of 11–15 MGIT samples plus M tuberculosis H37Rv 
Research in context
Evidence before this study
We searched PubMed for studies published before July 1, 2015, 
with no language restrictions, using the search terms “whole 
genome sequencing”, “diagnosis”, “infection”, 
“mycobacterium”, and “tuberculosis”. Full diagnosis of 
Mycobacterium tuberculosis consists of identiﬁ cation of the 
organism, establishment of antibiotic sensitivity proﬁ les, and 
outbreak investigation. During the last 5 years, whole-genome 
sequencing (WGS) has been increasingly used to assist aspects 
of this diagnostic pathway. Its primary use has been outbreak 
investigations, for which WGS provides higher-resolution 
outbreak tracing than does traditional typing. WGS has begun 
to be used to elucidate drug resistance proﬁ les for tuberculosis 
and discover new resistance-conferring mutations. In view of 
the slow (1–2 months) diagnostic time for tuberculosis with 
culture-based methods, introduction of molecular assays, 
including WGS, to replace aspects of the tuberculosis diagnostic 
pathway has been recognised to improve outbreak control and 
potentially expedite patient treatment. However, many barriers 
to widespread adoption of WGS have been raised. These barriers 
are high diagnostic costs and personnel eﬀ orts and an absence 
of automated sequence analysis pipelines and supporting IT 
infrastructure.
Added value of this study
In this study, we implement an end-to-end WGS-based 
diagnostic system for tuberculosis in eight laboratories in 
Europe and North America. Using a decentralised sequencing, 
centralised analysis model and a semi-automated 
bioinformatics pipeline, we sequenced newly positive 
mycobacterium cultures and generated diagnostic reports 
identifying the mycobacteria present, and for tuberculosis, 
predicted resistance to ﬁ rst-line and second-line antibiotics 
and did outbreak analysis. Prospective assessment of the 
WGS-based diagnostic system allows diagnostic accuracy to 
be directly compared with routine clinical diagnosis, which 
shows how WGS is scalable and how it could provide full 
diagnostic information weeks faster than routine clinical 
diagnostics could. Through a microcosting analysis 
comparing routine with WGS-based diagnostics, the ﬁ nancial 
feasibility of WGS-based diagnostics in high-income countries 
is established.
Implications of all the available evidence
WGS is now evidently capable of replacing traditional 
diagnostic procedures for tuberculosis in high-income settings. 
It oﬀ ers clear beneﬁ ts compared with traditional diagnostics, 
allowing rapid identiﬁ cation and control of outbreaks and 
minimising empirical treatment of patients through 
simultaneous ﬁ rst-line and second-line drug susceptibility 
prediction. Results from this study have led to a full feasibility 
study of use of WGS-based tuberculosis diagnostics in the UK, 
representing a paradigm shift in infectious disease diagnostics. 
Furthermore, as WGS technology continues to develop and 
portable systems become available, WGS will revolutionise 
diagnostics in low-income settings. 
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or BCG DNA (positive control) with MiSeq version 2 
2 × 150 bp paired-end read cartridges. We processed each 
sample once, repeating sequencing only for poor overall 
run performance. We deposited reads in the National 
Center for Biotechnology Information Short Read Archive 
(BioProject PRJNA268101 and PRJNA302362; appendix).
Staﬀ  doing WGS processing and analysis were 
masked to routine reference laboratory and clinical 
results. We shared MiSeq runs via Illumina BaseSpace 
and downloaded them at the Oxford centre for semi-
automated analysis by a bespoke bioinformatics pipe-
line (appendix). A gene presence or absence algorithm 
identiﬁ ed mycobacterial species (using a catalogue of 
169 sequenced mycobacterial strains). We mapped 
isolates identiﬁ ed as MTBC to the H37Rv reference 
genome (GenBank NC000962.2; Stampy version 
1.0.22) and examined them for mutations deemed to 
confer pheno typic resistance to isoniazid, rifampicin, 
etham butol, pyrazinamide, streptomycin, ﬂ uoro-
quinolones, or aminoglycosides on the basis of a 
published catalogue of high-conﬁ dence resistance-
determining alleles (appendix).6 A minimum sequen-
cing depth of ﬁ ve reads was needed to identify 
mutations; when we found more than one base at a 
single site, if the minority variant consisted of at least 
10% of the total base calls and had a depth of at least 
ﬁ ve reads, we predicted a mixed phenotype. We 
identiﬁ ed cases compatible with trans mission from a 
published database of 2191 UK MTBC sequences, 
representing all worldwide lineages, as previously 
described (using a threshold of 12 or fewer single-
nucleotide poly morphisms (SNPs) on the basis of 
maximum diversity within diﬀ erent body sites and 
over time within a patient, and within household 
outbreaks; appendix).13
We estimated sequencing quality with several methods. 
For all specimens, we mapped the ﬁ rst 50 000 reads 
(Bowtie version 2.2.0) to the human genome 
(GRCh37/hg19) and nasal and mouth ﬂ ora in the National 
Institutes of Health Human Microbiome Project. To 
verify that this sample was random, we selected 1% of 
reads using SAMtools 1.2 (SAMtools view –s option). We 
mapped these randomly selected reads using the same 
methods and yielded the same results (data not shown). 
We assessed the number of reads mapping to these 
human, nasal, and mouth databases, guanine-cytosine 
(GC) content (expected to be about 65% for mycobacteria), 
the number of reads available for analysis, the number of 
reads mapping to the reference genome, and reference 
genome coverage as predictors of accurate species ident-
iﬁ cation using multivariable fractional polynomial 
logistic regression (Stata mfp; backwards elimination 
threshold p=0·05) in Stata 13.1, treating each specimen as 
an independent observation.21 We reported quality control 
data to the sequencing centre together with mycobacterial 
species, and for MTBC, drug susceptibility predictions 
and closest genomic match (appendix).
We gathered anonymised routine diagnostic data from 
local clinical laboratories and regional mycobacterial 
reference laboratories after WGS processing. All MTBC 
duplicate specimens were identiﬁ ed by the participating 
centres and analysis of drug resistance and outbreak 
incidence done with and without removal of duplicates 
(appendix). We did not identify duplicates for non-MTBC 
specimens. If routine and WGS results diﬀ ered, we did 
additional quality checking and routine workﬂ ow assays; 
we did not repeat WGS. We calculated conﬁ dence 
n
Routine methods and WGS identiﬁ cation failed 9
Routine methods failed 2*
Identiﬁ ed by routine methods 345 (100%)
Concordant 322 (93%)
M tuberculosis complex 157 (46%)
M avium complex 71 (21%)
M abscessus complex 39 (11%)
M gordonae 18 (5%)
M xenopi 11 (3%)
M tuberculosis complex (BCG) 8 (2%)
M kansasii 6 (2%)
M malmoense 3 (1%)
M fortuitum 2 (1%)
M szulgai 2 (1%)
M tuberculosis complex (M africanum) 2 (1%)
M celatum 1 (<1%)
M lentiﬂ avum 1 (<1%)
M tuberculosis complex and M avium complex 1 (<1%)
Part concordant 10 (3%)
WGS gained one species 5 (1%)†
WGS missed one species 3 (1%)‡
WGS identiﬁ ed related species 1 (<1%)§
WGS identiﬁ ed subspecies 1 (<1%)¶
Discordant 3 (1%)||
WGS failed 10 (3%)
Data in parentheses are % of specimens identiﬁ ed by routine methods. 
M=Mycobacterium. WGS=whole-genome sequencing. *WGS identiﬁ ed M avium 
complex (good quality WGS; 32 [97%] of 33 genes identiﬁ ed) and 
M kumamotonense (poor quality WGS; 58 [58%] of 100 genes identiﬁ ed). †One 
routine M tuberculosis complex (MTBC): WGS identiﬁ ed MTBC plus M avium 
complex (retesting not possible); three routine M avium complexes: WGS 
identiﬁ ed MTBC plus M avium complexes (two retesting supported routine; one 
supported WGS); one routine M abscessus complex: WGS identiﬁ ed M abscessus 
plus M avium complex (retesting supported routine); appendix. ‡One routine 
MTBC plus M avium complex: WGS identiﬁ ed MTBC (retesting supported WGS); 
two routine MTBC plus M avium complex: WGS M avium complex (one poor 
quality WGS; two [6%] of 33 genes identiﬁ ed; one unable to retest); appendix. 
§One undescribed mycobacterial species similar to M avium: WGS identiﬁ ed 
M avium complex (appendix). ¶One routine M fortuitum: WGS identiﬁ ed M 
fortuitum-acetamidolyticu m (poor quality WGS; 33 [33%] of 100 genes identiﬁ ed); 
appendix. ||One routine M kansasii: WGS identiﬁ ed M avium complex (routine 
testing subsequently conﬁ rmed M avium complex); one routine M avium 
complex: WGS M scrofulaceum (poor quality WGS; one [1%] of 72 genes 
identiﬁ ed); one routine MTBC: WGS identiﬁ ed M abscessus complex (good quality 
WGS; 38 [95%] of 40 genes identiﬁ ed; unable to retest specimen); appendix. 
Table 1: Concordance between single WGS and routine laboratory 
methods for mycobacterial speciation
For the Human Microbiome 
Project see http://www.
hmpdacc.org
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intervals for WGS sensitivity, speciﬁ city, or accuracy 
compared with routine diagnostics in Stata 13.1 (Stata cii).
To assess the ﬁ nancial viability of WGS-based 
diagnostics, we did a microcosting analysis at a local 
clinical laboratory (John Radcliﬀ e Hospital, Oxford, UK) 
and regional reference laboratory (Birmingham 
Heartlands Hospital Trusts, Birmingham, UK). We 
collected data using questionnaires based on standard 
operating procedures, expert consultations, and inter-
views with laboratory staﬀ . Questionnaires were 
completed by clinical scientists doing mycobacterial 
processing and ﬁ nancial managers, who collected costs 
associated with staﬀ  time, error rates, equipment, and 
consumables (appendix). We obtained basic cost data 
(staﬀ  time, consumables, and equipment only) via 
interview with clinical scientists for second-line 
phenotypic DST (done at the National Mycobacterial 
Reference Laboratory, London, UK). We annualised costs 
using the throughput of the Birmingham regional 
reference laboratory for 2014.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication. 
Results
Each participating site collected positive MGIT samples 
for between 9 and 158 days (appendix p 19). 27 (21%) of 
127 MTBC patients provided two to six specimens. 
Median time from positivity to inactivation was 4 days 
(IQR 1–5; 96 recorded). Median read depth, based on 
read length and number of reads mapping to the 
reference genome, was 73 (IQR 36–99; see appendix for 
alternative read-depth metrics). 
356 MGIT specimens were submitted. 345 (97%) were 
identiﬁ ed to species or complex by routine diagnostic 
workﬂ ows (table 1). In 326 (94%) cases, both Hain and 
WGS assays identiﬁ ed a single species, of which three 
(1%) were discordant. Two species were identiﬁ ed in nine 
(3%) of cases, of which eight (89%) were discordant for 
one of the species. WGS predictions were concordant 
with routine results in 322 (93% [95% CI 90–96]) of 
345 specimens (including duplicate specimens). Hain 
and WGS assays identiﬁ ed MTBC in 168 (52%) of 
322 concordant specimens. Of the discordant isolates, 
three (13%) of 23 were MTBC cases identiﬁ ed by the 
reference laboratory alone, three (13%) were MTBC cases 
identiﬁ ed by WGS alone, and two (9%) were identiﬁ ed in 
a co-infection by either WGS or the reference laboratory 
(but not both). In a further six (26%) MTBC cases 
(identiﬁ ed by the reference laboratory), WGS failed. 
Overall, MTBC was identiﬁ ed with 95% (95% CI 91–98) 
sensitivity and 98% (95–100) speciﬁ city (including 
duplicate specimens). Causes of discordant results were 
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mixed or contaminated samples and poor quality 
sequencing. Failure to identify MTBC increased signif-
icantly and independently if GC content fell below 50% 
(showing low-GC non-mycobacterial DNA contam-
ination) or if the total number of sequencing reads fell 
below 1 million (appendix p 16; p<0·005).
For 168 MTBC specimens identiﬁ ed by WGS and routine 
diagnosis, 628 (93% [95% CI 91–95]) of 672 WGS-based 
ﬁ rst-line drug susceptibility predictions were concordant 
with reference laboratory DST. After deduplication, 467 
(92% [89–94]) of 508 predictions across 127 specimens 
were concordant. Overall, WGS resistance prediction 
failed on 63 occasions across 15 specimens. Eight (53%) 
specimens failed all predictions, four (27%) failed 
aminoglycosides only, two (13%) failed rifampicin only, 
and one (7%) failed pyrazinamide only. When WGS 
prediction failed, all but one DST result was sensitive (one 
DST also failed). WGS made an additional 434 (mainly 
second-line) predictions when DST was not done, 
including four specimens with monoresistance to second-
line drugs (appendix). In 13 cases (across 11 specimens and 
four drugs), resistance-conferring mutations and wild-type 
alleles occurred as a mixture, preventing phenotypic 
predictions. We noted the highest number of mixtures (7 
[4%] of 168 specimens) in genes conferring resistance to 
aminoglycosides (table 2). Eight WGS predictions (across 
six specimens and six drugs) were discordant with DST. Of 
seven phenotypically resistant specimens with no 
resistance-conferring mutations in the catalogue, six (86%) 
contained unclassiﬁ ed variants in the relevant genes 
(appendix). Of the 127 deduplicated specimens, WGS 
reported 22 (17%) incidences of drug-resistant MTBC, of 
which ﬁ ve (23%) were M bovis (monoresistant to 
pyrazinamide). Four (3%) of 127 patients were infected 
with multidrug-resistant tuberculosis.
Pairwise SNP distances between 16 UK-sourced 
H37Rv-positive controls were all zero; one, from 
diﬀ erent starting material, was eight SNPs or fewer 
from other replicates. 68 (40%) of 168 MTBC specimens 
were 12 SNPs or fewer from at least one other specimen 
in the available UK database or previously sequenced in 
this study; however, 33 (49%) of these specimens 
(15 patients) were linked only to another specimen from 
the same patient.13 In the 127 patients with MTBC, the 
median pairwise distance to the next nearest patient was 
113 (IQR 48–173). 22 (17%) patients with MTBC (19 [86%] 
UK and three [14%] non-UK; 35 specimens) were linked 
to diﬀ erent patients. This number included ﬁ ve (23%) 
patients (four [80%] UK; one [20%] non-UK) with 
vaccine-strain BCG and two (9%) patients linked only to 
each other (same non-UK centre). In total, 15 (16% 
[95% CI 10–26]) of 91 UK patients studied were linked to 
nine outbreak clusters in the UK database; including 
two (13%) patients unexpectedly linked to an outbreak 
cluster (subsequently conﬁ rmed epidemiologically; pilot 
cluster 6; appendix) and two (13%) from diﬀ erent UK 
regions linked to an isoniazid-resistant cluster in a third 
region (subsequently conﬁ rmed epidemiologically and 
via MIRU-VNTR; appendix). Eight (89%) of nine 
outbreak clusters were already being investigated by 
local health protection teams, with well established epi-
demio logical links supported by MIRU-VNTR data 
(available for eight [53%] of 15 UK study patients linked 
to these pre-existing clusters). The remaining cluster 
involved patients infected with multidrug-resistant 
tuberculosis. In this case, WGS provided the ﬁ rst 
diagnosis and outbreak alert (panel).
Unadjusted median time from MGIT positivity to DST 
reporting was 25 days (IQR 14–32), whereas for ﬁ nal 
reports, including MIRU-VNTR genotype reporting, it 
was 31 days (IQR 21–44); similarly, full WGS-based 
reports were available in 31 days (IQR 21–60). WGS 
processing delays were driven by sample batching for 
sequencing and delays in sharing sequencing data 
(ﬁ gure 2). Additionally, we adhered to a 5 day working 
week for WGS-based processing, rather than the 7 day 
working week in clinical laboratories. After WGS 
sharing, we generated full diagnostic reports in a median 
Panel: Early multidrug-resistant tuberculosis diagnosis 
and outbreak discovery
Two patients were linked to a previously sequenced extremely 
drug-resistant tuberculosis case to form a new cluster (ﬁ gure 1). 
The ﬁ rst case, for which sequencing and analysis was 
completed a week after Mycobacteria Growth Indicator Tube 
positivity, was seven single-nucleotide polymorphisms from a 
2010 isolate from a patient residing about 300 miles away.13 
The study specimen was predicted to be resistant to isoniazid, 
rifampicin, and amino glycosides, whereas the 2010 isolate was 
pheno typically and genotypically resistant to the same drugs 
and to ﬂ uoroquinolones (with gyrAA90 mutation). Because the 
study specimen had yet to be processed by the reference 
laboratory, whole-genome sequencing (WGS) provided the ﬁ rst 
multidrug-resistant tuberculosis alert to the participating 
centre. This patient, with smear-positive pulmonary 
tuberculosis, was receiving ﬁ rst-line treatment in the 
community while awaiting laboratory results. Prompted by 
WGS, urgent Hain MTBDRplus and MTBDRsl assays were done 
by the reference laboratory, conﬁ rming WGS drug resistance 
predictions. Mycobacterial interspersed repetitive unit-variable-
number tandem repeat was identical across the 2010 and study 
isolates, conﬁ rming the genetic relation. The patient was 
admitted to hospital for appropriate treatment on the basis of 
reference laboratory Hain results. Epidemiological investigation 
showed that both patients originated from the same European 
country. 2 months later, a second study specimen from the 
same centre was zero SNPs from the ﬁ rst specimen, with an 
identical drug resistance proﬁ le, consistent with direct 
transmission.13 Mycobacterial interspersed repetitive unit-
variable-number tandem repeat again conﬁ rmed the genetic 
relation, although no epidemiological links between these 
patients have yet been identiﬁ ed.
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of 5 days (IQR 3–7). The time delay from sample 
batching would be minimised in high-throughput 
laboratories. To estimate the potential speed of WGS-
based diagnosis, we compared the recorded times from 
2 days before sequencing (to allow for sample preparation 
and 7 day working weeks) to WGS report generation 
with reference laboratory reporting times (using the date 
that specimens were sent to the reference laboratory as 
the starting point). We found that reference laboratory 
reports were generated a median of 15 days (IQR 9–25) 
slower than we could produce WGS reports for drug 
resistance (median 24 days [IQR 20–33] vs 8 days [6–9]) 
and 21 days (14–32) slower for relatedness (32 days 
[22–42] vs 9 days [6–10]; ﬁ gure 2). 
The cost of WGS-based diagnosis, routine diagnostic 
costs for a non-tuberculous mycobacteria (NTM; culture 
and species identiﬁ cation only), costs for a fully sensitive 
MTBC (culture, species identiﬁ cation, MIRU-VNTR, and 
ﬁ rst-line DST), and costs for a drug-resistant MTBC 
(culture, species identiﬁ cation, MIRU-VNTR, ﬁ rst-line 
and second-line DST if resistant to rifampicin) are shown 
in table 3 (detailed breakdown in appendix). Consumables 
were the main cost driver for all processes other than for 
DST, for which staﬀ  costs dominated. 
Costs (calculated with reported throughput for 2014) 
for routine diagnostic workﬂ ows were £518 per culture-
positive specimen, consisting of MGIT culture for all 
samples received, species identiﬁ cation for culture-
positive specimens, and MIRU-VNTR and DST for 
MTBC-positive specimens. For WGS-based diagnosis, 
consisting of MGIT culture for all samples received and 
WGS for culture-positive specimens, the per-culture-
positive specimen cost would be £481, which is 7% 
cheaper than are routine diagnostics. To do DST as per 
present workﬂ ows alongside WGS would cost £540 per 
culture-positive specimen, which is 4% more expensive 
Figure 1: Details of pilot study cluster 7
(A) Timeline of the full WGS-based, routine-based, and reference laboratory-based diagnosis for patient 1 (red circles represent processes needed by both routine or 
reference and WGS processes, green circles represent routine or reference processes, and blue circles represent WGS processes); (B) the genomic relation between 
cluster isolates as established by WGS nearest neighbours; (C) detail of the seven SNP diﬀ erences between cluster isolates; (D) detail of the resistance-conferring 
mutations identiﬁ ed in the 2010 isolate and the two study patients. A=adenine. C=cytosine. G=guanine. MIRU-VNTR=mycobacterial interspersed repetitive unit-
variable-number tandem repeat. MGIT=Mycobacteria Growth Indicator Tube. MTBC=Mycobacterium tuberculosis complex. SNP=single-nucleotide polymorphism. 
T=thymine. WGS=whole-genome sequencing. WT(S)=wild-type (susceptible). *Mutation conferring resistance to ﬂ uoroquinolones. †Wild-type (sensitive). 
‡Heterozygous at this position (four wild-type base calls A vs 29 resistance-conferring variant base calls G).
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than are routine diagnostics (table 3). Increasing 
sample throughput decreased costs overall (table 3, 
appendix). Variation in sequencing batch size, 
throughput, error rates, equipment, consumables, and 
overhead costs could alter overall WGS costs by up to 
17% (appendix).
Discussion
In this prospective, multicentre, international pilot 
study, we assessed the real-time performance and cost 
of WGS for laboratory diagnosis of mycobacterial 
infection. With use of prototype software and only one 
sequencing attempt, 93% of mycobacteria were con-
cordant with routine laboratory complex or species-level 
identiﬁ cation and 93% of susceptibility predictions for 
MTBC isolates were concordant with DST. The same 
sequencing data linked 16% of UK patients to an out-
break, identiﬁ ed an inter-regional cluster of isoniazid-
resistant MTBC, and discovered transmission of 
multi drug-resistant tuber culosis, substantially hasten-
ing diagnosis and appropriate treatment of one patient. 
Generation of full diagnostic information by WGS was 
7% cheaper than by routine methods.
This study provides proof-of-principle in high-income 
countries that local sample collection and sequencing 
with centralised analysis can be applied on an inter-
national scale. The median of 5 days between WGS data 
sharing and full diagnostic report availability com pares 
favourably with present diagnostic workﬂ ows.5,12 The 
resistotyping and nearest-neighbour algorithms are rapid 
and scalable, retaining the resolution of whole-genome 
analysis. Our workﬂ ow does not depend on the speciﬁ c 
algorithms used, which could easily be reﬁ ned and 
improved. Consequently, Public Health England is 
currently assessing the suitability of WGS from early-
positive MGIT cultures to replace routine clinical 
tuberculosis processing.22
For species identiﬁ cation, Hain assays are capable of 
detecting 40 NTM and M tuberculosis species or 
complexes. The sequenced catalogue of 169 mycobacterial 
type strains used here provided broad diagnostic capacity. 
Although the gene presence or absence algorithm could 
not distinguish between diﬀ erent complex members, for 
MTBC, this issue was resolved by phylogenetic analysis 
after reference genome mapping. This approach could 
be extended to other species’ complexes.
Figure 2: Timings for whole-genome sequencing and routine methods
(A) Time taken to extract DNA from individual Mycobacteria Growth Indicator 
Tube aliquots and do each sequencing run (one point per isolate); (B) time from 
the sequencing run ﬁ nishing to sharing of data to generation of reports; (C) time 
taken for reference laboratory reports of resistance and relatedness to be generated 
compared with whole-genome sequencing (WGS) reports (one point per isolate). 
Reference laboratory timings calculated from the sending of samples to the 
reference laboratory; adjusted WGS timings calculated with an assumption of 
2 days (laboratory processing time) between the date samples were sent to the 
reference laboratory and the date sequencing was done (minimising batch eﬀ ects); 
data immediately shared. Points below 0 show that reference laboratory reports 
were generated faster than WGS reports were. *Receiving of resistance report from 
reference laboratory compared with generation of resistance prediction by WGS. 
†Receiving of ﬁ nal report, including mycobacterial interspersed repetitive 
unit-variable-number tandem repeat data, from reference laboratory compared 
with ﬁ nal WGS reports being generated (including relatedness).
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WGS drug susceptibility predictions were highly 
concordant with the reference standard, simultaneously 
predicting ﬁ rst-line and second-line susceptibilities at no 
additional cost, despite incomplete knowledge of genotype–
phenotype relations. Overall, the 17% incidence of drug 
resistance and 3% incidence of multidrug-resistant 
tuberculosis, as assessed by WGS, was well below 
occurrence in high-incidence settings.10 Of eight discrepant 
results, four had unclassiﬁ ed variants not in our 
prespeciﬁ ed catalogue, but with evidence of association 
with drug resistance in the wider scientiﬁ c literature. 
Investigations have provided robust, evidence-based 
resistance prediction catalogues for use in future invest-
igations and algorithms for the iterative addition of new or 
rare mutations to the prediction catalogue, with phenotypic 
support.6,8,10,14 No previously described mutations could 
explain pheno typic resistance for the remaining specimens; 
with only one sequencing attempt per isolate, these data 
could not be veriﬁ ed. Drug resistance might also be 
mediated by post-transcriptional or post-translational 
protein modiﬁ cations and eﬄ  ux pump activation.23–25 Such 
resistance mechanisms remain little studied and should be 
investigated further as genotype–phenotype com parisons 
continue. However, DST methods for drugs other than 
isoniazid and rifampicin are also imperfect.26,27
Minority variants complicating phenotypic predictions 
were present in 12 isolates. These variants might be due to 
emerging resistance or mixed infection within the patient, 
sample contamination with nasopharyngeal ﬂ ora, or 
cross-contamination. We noted more mixed calls (4%) in 
the 16S gene (rrs) conferring aminoglycoside resistance 
than in the other resistance-conferring genes examined, 
potentially due to similar reads from other bacterial 
species mapping to the H37Rv reference. Because MGITs 
are inoculated with primary clinical samples, removal of 
other bacterial DNA, and subsequent resistance prediction 
where removal has been incomplete, pose challenges.20 
Despite this challenge, overall sensitivity was similar to 
that reported from other available drug susceptibility 
prediction tools and with use of pure-culture samples.6,8 
Throughput 
in 2014 (n)*
Total per 
sample in 
2014 (£)
10% fewer 
samples per 
year (£)
10% more 
samples per 
year (£)
WGS and routine clinical workﬂ ows
MGIT culture 15 265 52·39 52·90 51·97
Cepheid Xpert MTB/RIF 617 99·66 102·35 97·44
WGS workﬂ ow only
WGS 2207 118·55 120·16 117·26
Routine clinical workﬂ ows only
Identiﬁ cation assays 2207 55·05 55·28 54·87
Hain MTBC 866 ·· ·· ··
Hain CM/AS 1341 ·· ·· ··
MIRU-VNTR 866 107·75 110·89 105·18
First-line DST 866 135·47 137·12 134·13
Limited second-line DST† 62 93·01 93·24 92·83
Second-line DST‡ 62 101·27 104·24 98·86
WGS workﬂ ow scenarios
MGIT culture and WGS ·· 170·94 173·06 169·23
MGIT culture and WGS and ﬁ rst-line DST ·· 306·41 310·18 303·36
MGIT culture and WGS and ﬁ rst-line DST and full second-line DST ·· 500·68 507·66 495·05
Routine clinical workﬂ ow scenarios
Culture and identiﬁ cation assays ·· 107·44 108·18 106·84
Culture and identiﬁ cation assays and MIRU-VNTR and ﬁ rst-line DST ·· 350·66 356·19 346·15
Culture and identiﬁ cation assays and MIRU-VNTR and ﬁ rst-line DST and full second-line DST ·· 544·93 553·69 537·84
Total workﬂ ow costs
WGS-based diagnostics ·· 480·91 486·01 476·75
WGS-based diagnostics and ﬁ rst-line and full second-line DST ·· 539·53 545·37 534·73
Routine clinical workﬂ ow-based diagnostics ·· 518·31 524·00 513·64
Error rates reported in this study: 1% microscopy, 2% MGIT culture, 10% Cepheid Xpert MTB/RIF, <1% species identiﬁ cation (Hain ID), 13% DNA extraction for WGS, 4% WGS, 
1% WGS data analysis, 10% MIRU-VNTR, and <1% DST. WGS=whole-genome sequencing. MGIT=Mycobacteria Growth Indicator Tube. MIRU-VNTR=mycobacterial 
interspersed repetitive unit-variable-number tandem repeat. DST=drug susceptibility testing. *Number reported in the Birmingham reference laboratory (Birmingham, UK) 
for 2014. Negative tests not counted for Hain GenoType MTBC (Hain Lifescience, Nehren, Germany), Hain GenoType Mycobacterium CM/AS, second-line DST, Hain 
GenoType MTBDRplus, or Hain GenoType MTBDRsl. †Done at the Birmingham clinical laboratory. ‡Done at a second reference laboratory (London, UK). Based on staff time, 
consumables, and equipment only.
Table 3: Total cost per sample by process, accounting for error rates
Articles
www.thelancet.com/respiratory   Published online December 3, 2015   http://dx.doi.org/10.1016/S2213-2600(15)00466-X 9
Throughout this investigation, WGS results were provided 
together with sequence quality feedback to allow laboratory 
staﬀ  to improve interpretation and practice. Other 
methods provide a small amount of data quality feedback 
and drug resistance identiﬁ cation, but do not provide 
species or outbreak analysis.6,8 Although WGS was not 
repeated in this study, retesting isolates when species 
identiﬁ cation, DST, or MIRU-VNTR deliver questionable 
results is routine in diagnostic laboratories, and such a 
system will be implemented for WGS. As more specimens 
are sequenced than at present, robust algorithms to 
identify isolates for resequencing will be developed to 
prevent inaccurate results being reported and improve 
WGS sensitivity and speciﬁ city.
16% of sequenced UK MTBC isolates were linked to one 
of nine UK outbreak clusters, including one spanning 
three regions. Large geographical distances separating 
genetically related isolates have been previously reported,10 
with the authors concluding that low genetic divergence 
might not always represent transmission or that casual 
contact might be important in MTBC transmission. 
Application of WGS on a wide scale, as shown by the US 
Food and Drug Administration,28 will only serve to 
increase the number of links detected between patients 
and outbreaks. Most surprisingly during this investigation, 
WGS diagnosed multidrug-resistant tuberculosis in one 
patient, only subsequently conﬁ rmed by the reference 
laboratory. This diagnosis directly aﬀ ected the individual 
patient’s care and reduced onward transmission risk. 
Identiﬁ cation of a second patient with genetically identical 
multidrug-resistant tuberculosis shows the need to rapidly 
identify infected patients to minimise the risk of 
transmission.
An often cited obstacle to clinical implementation of 
WGS is cost.29–31 For the laboratories and workﬂ ows costed 
here, high WGS costs for NTM diagnosis were 
outweighed by savings made in MTBC diagnosis, leading 
to an overall saving of 7% per year for a reference centre. 
If present DST workﬂ ows are continued alongside WGS, 
costs would be 4% greater per year than with present 
workﬂ ows alone. However, these additional costs would 
be mitigated by replacement of any molecular DST done 
alongside phenotypic DST with WGS. The cost-
eﬀ ectiveness of replacement of phenotypic with other 
rapid genotypic assays in terms of patient care has already 
been shown31 and is probably similar for WGS. The 
decentralised-sequencing, centralised-analysis model 
used in this study minimises computational and technical 
support costs. WGS costs could fall further when 
implemented diagnostically, which will need less skilled 
staﬀ  than at present. However, availability of skilled staﬀ  
is likely to remain a key limitation of adoption of WGS in 
low-income settings. Fully automated analysis and 
reporting and strategic placement of benchtop sequencers 
would also reduce diagnostic delays, as reported in this 
study. Furthermore, progress in develop ment of direct-
from-sample and point-of-care WGS is continuing, and, 
combined with the analysis algorithms shown, will 
revolutionise MTBC diagnosis.31,32
WGS allows simultaneous prediction of mycobacterial 
species, ﬁ rst-line and second-line drug resistance, the 
ability to monitor emergence of new resistance mech-
anisms, and high-resolution outbreak monitoring on a 
timescale weeks faster than with traditional diagnostics. 
Coupled with public health interventions, WGS will 
transform MTBC patient care and disease control and 
has the potential to transform diagnosis of other infect-
ious diseases.5 Furthermore, our cost estimates have 
shown that WGS-based diagnostics will provide value for 
money, demonstrating how WGS can replace myco-
bacterial diagnostic workﬂ ows from positive MGIT 
culture in high-income countries.
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